The stock price of ARS Pharmaceuticals Inc (NASDAQ: SPRY) has plunged by -6.84 when compared to previous closing price of 9.06, but the company has seen a -8.66% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-01 that ARS Pharmaceuticals, Inc. (SPRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
Is It Worth Investing in ARS Pharmaceuticals Inc (NASDAQ: SPRY) Right Now?
The 36-month beta value for SPRY is also noteworthy at 0.86. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SPRY is 42.16M, and at present, short sellers hold a 13.04% of that float. The average trading volume of SPRY on April 19, 2024 was 674.53K shares.
SPRY’s Market Performance
SPRY stock saw a decrease of -8.66% in the past week, with a monthly decline of -0.24% and a quarterly a decrease of 38.82%. The volatility ratio for the week is 5.25%, and the volatility levels for the last 30 days are 5.99% for ARS Pharmaceuticals Inc (SPRY). The simple moving average for the last 20 days is -9.96% for SPRY stock, with a simple moving average of 33.32% for the last 200 days.
Analysts’ Opinion of SPRY
Many brokerage firms have already submitted their reports for SPRY stocks, with Leerink Partners repeating the rating for SPRY by listing it as a “Outperform.” The predicted price for SPRY in the upcoming period, according to Leerink Partners is $18 based on the research report published on March 05, 2024 of the current year 2024.
SPRY Trading at -1.87% from the 50-Day Moving Average
After a stumble in the market that brought SPRY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.11% of loss for the given period.
Volatility was left at 5.99%, however, over the last 30 days, the volatility rate increased by 5.25%, as shares sank -2.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +29.85% upper at present.
During the last 5 trading sessions, SPRY fell by -8.66%, which changed the moving average for the period of 200-days by +25.41% in comparison to the 20-day moving average, which settled at $9.36. In addition, ARS Pharmaceuticals Inc saw 54.01% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRY starting from Tanimoto Sarina, who sale 100,000 shares at the price of $9.28 back on Apr 16 ’24. After this action, Tanimoto Sarina now owns 1,647,447 shares of ARS Pharmaceuticals Inc, valued at $928,005 using the latest closing price.
Lowenthal Richard E, the PRESIDENT AND CEO of ARS Pharmaceuticals Inc, sale 100,000 shares at $9.28 during a trade that took place back on Apr 16 ’24, which means that Lowenthal Richard E is holding 1,647,447 shares at $928,005 based on the most recent closing price.
Stock Fundamentals for SPRY
Current profitability levels for the company are sitting at:
- -2250.67 for the present operating margin
- -462.1 for the gross margin
The net margin for ARS Pharmaceuticals Inc stands at -1686.47. The total capital return value is set at -0.29.
Based on ARS Pharmaceuticals Inc (SPRY), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -216.3. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 18.0.
Currently, EBITDA for the company is -67.45 million with net debt to EBITDA at 1.05. When we switch over and look at the enterprise to sales, we see a ratio of 24792.55. The receivables turnover for the company is 0.04for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 96.85.
Conclusion
In summary, ARS Pharmaceuticals Inc (SPRY) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
